TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Galmed Pharmaceuticals ( (GLMD) ) has shared an update.
Galmed Pharmaceuticals announced its financial results for the third quarter of 2025, highlighting a net loss of approximately $2.0 million, an increase in research and development expenses, and a decrease in general and administrative expenses compared to the same period in 2024. The company also reported significant progress in its research collaborations, including promising results from a study on Aramchol’s effectiveness in combating drug resistance in gastrointestinal cancers, and a successful Phase 1 study of Aramchol Meglumine, which could enhance its market positioning and stakeholder confidence.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.
Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for liver, cardiometabolic, and gastrointestinal oncology indications. The company is primarily known for its work on Aramchol, a compound aimed at treating liver diseases, and is expanding its research to include oncological applications and other innovative drug candidates.
Average Trading Volume: 2,031,257
Technical Sentiment Signal: Sell
Current Market Cap: $4.5M
Learn more about GLMD stock on TipRanks’ Stock Analysis page.